tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RPRX Stock Latest News

Royalty Pharma upgraded to Buy from Neutral at UBS
The FlyRoyalty Pharma upgraded to Buy from Neutral at UBS
7d ago
RPRX
Royalty Pharma price target raised to $50 from $48 at Citi
PremiumThe Fly
Royalty Pharma price target raised to $50 from $48 at Citi
10d ago
RPRX
Royalty Pharma provides update on business performance
PremiumThe Fly
Royalty Pharma provides update on business performance
25d ago
RPRX
Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
PremiumThe Fly
Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
26d ago
RPRX
TEVA
Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
PremiumThe Fly
Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
28d ago
RPRX
Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
PremiumThe FlyRoyalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
1M ago
CHRO
RPRX
Royalty Pharma Announces Planned Legal Leadership Transition
Premium
Company Announcements
Royalty Pharma Announces Planned Legal Leadership Transition
2M ago
8K
RPRX
Royalty Pharma Gains From FDA Approval of MYQORZO
Premium
Company Announcements
Royalty Pharma Gains From FDA Approval of MYQORZO
2M ago
8K
RPRX
Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
PremiumThe Fly
Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
2M ago
NUVL
RPRX
Royalty Pharma price target raised to $45 from $42 at TD Cowen
PremiumThe Fly
Royalty Pharma price target raised to $45 from $42 at TD Cowen
2M ago
RPRX
Royalty Pharma, Denali Therapeutics enter $275M royalty funding agreement
PremiumThe Fly
Royalty Pharma, Denali Therapeutics enter $275M royalty funding agreement
2M ago
DNLI
RPRX
Denali Therapeutics, Royalty Pharma announce $275M royalty funding agreement
PremiumThe Fly
Denali Therapeutics, Royalty Pharma announce $275M royalty funding agreement
2M ago
DNLI
RPRX
Royalty Pharma downgraded to Hold from Buy at TD Cowen
PremiumThe FlyRoyalty Pharma downgraded to Hold from Buy at TD Cowen
3M ago
RPRX
Royalty Pharma 14.244M share Block Trade priced at $40.00
Premium
The Fly
Royalty Pharma 14.244M share Block Trade priced at $40.00
3M ago
RPRX
Royalty Pharma 14.244M share Block Trade; price range $40.00-$40.78
Premium
The Fly
Royalty Pharma 14.244M share Block Trade; price range $40.00-$40.78
3M ago
RPRX
Royalty Pharma Reports Strong Q3 2025 Results
PremiumCompany Announcements
Royalty Pharma Reports Strong Q3 2025 Results
3M ago
RPRX
Royalty Pharma’s Q3 2025 Earnings Call Highlights
PremiumCompany Announcements
Royalty Pharma’s Q3 2025 Earnings Call Highlights
3M ago
RPRX
Royalty Pharma reports Q3 portfolio receipts of $814M
PremiumThe Fly
Royalty Pharma reports Q3 portfolio receipts of $814M
3M ago
RPRX
Royalty Pharma raises FY25 portfolio receipts view to $3.2B-$3.25B
PremiumThe Fly
Royalty Pharma raises FY25 portfolio receipts view to $3.2B-$3.25B
3M ago
RPRX
Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M
PremiumThe FlyRoyalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M
3M ago
RPRX
Royalty Pharma price target lowered to $54 from $55 at Morgan Stanley
Premium
The Fly
Royalty Pharma price target lowered to $54 from $55 at Morgan Stanley
4M ago
RPRX
Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating
Premium
Ratings
Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating
4M ago
RPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >